What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA) , Matinas BioPharma (MTNB) , VYNE Therapeutics (VYNE) , Acasti Pharma (ACST) , Onconova Therapeutics (ONTX) , TherapeuticsMD (TXMD) , Bionano Genomics (BNGO) , DURECT (DRRX) , Geron (GERN) and Heat Biologics (HTBX) .

NASDAQ:MLND

Millendo Therapeutics (MLND) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free MLND Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $3.21
▼
$3.34
50-Day Range: $3.06
▼
$5.84
52-Week Range: $0.92
▼
$16.95

Volume: 682,179 shs
Average Volume: 1.52 million shs
Market Capitalization: $62.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Millendo Therapeutics alerts:

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Millendo Therapeutics Stock (NASDAQ:MLND)

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

Click here to download your report

MLND Stock News Headlines

March 20, 2024 | msn.com

A lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about access

March 7, 2024 | msn.com

Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

January 11, 2024 | markets.businessinsider.com

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

December 5, 2023 | msn.com

Why Is Clearmind Medicine (CMND) Stock Up 50% Today?

November 6, 2023 | markets.businessinsider.com

Maxim Group Maintains Their Buy Rating on Mind Medicine (MMED)

March 15, 2023 | benzinga.com

Expert Ratings for Decibel Therapeutics

December 29, 2022 | insidermonkey.com

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call Transcript

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

December 29, 2022 | yahoo.com

Clearmind Medicine Announces Shareholders Meeting Results

June 3, 2022 | finance.yahoo.com

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

May 31, 2022 | finance.yahoo.com

DTx Pharma Appoints Michael Huang, MD as Chief Medical Officer

May 19, 2022 | finance.yahoo.com

Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

May 16, 2022 | seekingalpha.com

Mind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcript

May 15, 2022 | finance.yahoo.com

Clearmind Announces Pre-IND Meeting Date with FDA

See More Headlines

Receive MLND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MLND
CUSIP: N/A
CIK: N/A
Web: www.millendo.com
Phone: 734 845 9000
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -91.03%
Return on Assets: -72.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.39
Quick Ratio: 6.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.78 per share
Price / Book: 1.84

Miscellaneous

Outstanding Shares: 19,043,000
Free Float: N/A
Market Cap: $62.27 million
Optionable: Not Optionable
Beta: 0.48

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Competitors

View All Competitors

MLND Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Millendo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

This page (NASDAQ:MLND) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Millendo Therapeutics (MLND) Stock Price, News & Analysis

About Millendo Therapeutics Stock (NASDAQ:MLND)

MLND Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Competitors

MLND Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info